Litcius/Paper detail

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Sjoukje F. Oosting, Astrid A.M. van der Veldt, Rudolf S.N. Fehrmann, Corine H. GeurtsvanKessel, Rob van Binnendijk, Anne‐Marie C. Dingemans, Egbert F. Smit, T. Jeroen N. Hiltermann, Gerco den Hartog, Mathilda Jalving, Tatjana T Westphal, Arkajyoti Bhattacharya, Faye de Wilt, Annemarie Boerma, L. van Zijl, Guus F. Rimmelzwaan, Pia Kvistborg, Cécile A. C. M. van, Nynke Y. Rots, Debbie van Baarle, John B.A.G. Haanen, Elisabeth G.E. de Vries

2022The Lancet Oncology26 citationsDOIOpen Access PDF

Topics & Concepts

MedicineVaccinationImmunotherapyCancerInternal medicineImmunogenicityChemotherapyImmune systemOncologyImmunologySARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impactsCancer Immunotherapy and Biomarkers